Top

Published in:

01-04-2014 | Adis Drug Evaluation

Radium-223 Dichloride: A Review of Its Use in Patients with Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases

Authors: Matt Shirley, Paul L. McCormack

Published in: Drugs | Issue 5/2014

Abstract

Radium-223 dichloride (Xofigo^®; formerly Alpharadin™) [hereafter referred to as radium-223] is a first-in-class alpha particle-emitting radiopharmaceutical that has recently been approved for the treatment of patients with castration-resistant prostate cancer (CRPC) with symptomatic bone metastases and no known visceral metastatic disease. Radium-223 is a calcium mimetic, which targets bone, delivering cytotoxic radiation to the sites of bone metastases. In the recently reported Alpharadin™ in Symptomatic Prostate Cancer (ALSYMPCA) phase III study, radium-223 was associated with significantly improved overall survival compared with placebo, making it the first bone-targeted CRPC therapy for which an overall survival benefit has been demonstrated. The ALSYMPCA study also demonstrated the beneficial effects of radium-223 on disease-related symptomatic skeletal events, pain and health-related quality of life. Radium-223 was generally well tolerated, being associated with low rates of myelosuppression and generally mild gastrointestinal adverse events. Thus, radium-223 is a valuable addition to the treatment options for this poor-prognosis population.

Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRef

Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180–92.PubMedCrossRef

Alva A, Hussain M. The changing natural history of metastatic prostate cancer. Cancer J. 2013;19(1):19–24.PubMedCrossRef

Carles J, Castellano D, Climent MÁ, et al. Castration-resistant metastatic prostate cancer: current status and treatment possibilities. Clin Transl Oncol. 2012;14(3):169–76.PubMedCrossRef

El-Amm J, Aragon-Ching JB. The changing landscape in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Med Oncol. 2013;5(1):25–40.PubMedCentralPubMedCrossRef

Mukherji D, Eichholz A, De Bono JS. Management of metastatic castration-resistant prostate cancer: recent advances. Drugs. 2012;72(8):1011–28.PubMedCrossRef

Pochon S. Drugs in clinical development for prostate cancer: summary and table. Pharm Med. 2011;25(6):387–404.CrossRef

Amaral TMS, Macedo D, Fernandes I, et al. Castration-resistant prostate cancer: mechanisms, targets, and treatment. Prostate Cancer. 2012;2012(327253):1–11.CrossRef

Cookson MS, Roth BJ, Dahm P, et al. Castration-resistant prostate cancer: AUA guideline. J Urol. 2013;190(2):429–38.PubMed

10.

Omlin A, Pezaro C, Mukherji D, et al. Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. Eur Urol. 2013;64(2):300–6.PubMed

11.

Saylor PJ, Lee RJ, Smith MR. Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol. 2011;29(27):3705–14.PubMedCentralPubMedCrossRef

12.

Lange PH, Vessella RL. Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev. 1999;17(4):331–6.CrossRef

13.

Saad F, Hotte SJ. Guidelines for the management of castrate-resistant prostate cancer. Can Urol Assoc J. 2010;4(6):380–4.PubMedCentralPubMedCrossRef

14.

Lewington VJ. Bone-seeking radionuclides for therapy. J Nucl Med. 2005;46(1 Suppl):38S–47S.PubMed

15.

Lewis B, Sartor O. Radiation-based approaches for therapy and palliation of advanced prostate cancer. Curr Opin Urol. 2012;22(3):183–9.PubMedCrossRef

16.

US FDA. Xofigo (radium Ra 223 dichloride) injection: prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203971lbl.pdf. Accessed 24 Feb 2014.

17.

European Medicines Agency. Xofigo: summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002653/WC500156172.pdf. Accessed 24 Feb 2014.

18.

Heier-Baardson H, Dornish M. Lack of protective effect by hypoxia on alpha particle radiation from radium-223 [abstract no. 855]. EJC Suppl. 2010;8(5):216.CrossRef

19.

Henriksen G, Fisher DR, Roeske JC, et al. Targeting of osseous sites with α-emitting ²²³Ra: comparison with the β-emitter ⁸⁹Sr in mice. J Nucl Med. 2003;44(2):252–9.PubMed

20.

Nilsson S, Larsen RH, Fosså SD, et al. First clinical experience with α-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11(12):4451–9.PubMedCrossRef

21.

Nilsson S, Franzén L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007;8(7):587–94.PubMedCrossRef

22.

Chittenden S, Hindorf C, Aksnes A, et al. Dosimetry and pharmacokinetics of ²²³Ra chloride in patients with bone metastases due to hormone refractory prostate cancer [abstract no. P0019]. Eur J Nucl Med Mol Imaging. 2012;39(2 Suppl):S308–9.

23.

Lewington V, Parker C, Hindorf C, et al. Radium-223 chloride, a first-in-class alpha-pharmaceutical for patients with castration-resistant prostate cancer (CRPC) and bone metastases: biodistribution/dosimetry compared to overall safety profile [abstract no. e15009]. J Clin Oncol. 2010;28(15 Suppl).

24.

Carrasquillo JA, O’Donoghue JA, Pandit-Taskar N, et al. Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40(9):1384–93.PubMedCrossRef

25.

McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med. 1998;25(9):1341–51.PubMedCrossRef

26.

Bruland ØS, Nilsson S, Fisher DR, et al. High-linear energy transfer irradiation targeted to skeletal metastases by the α-emitter ²²³Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res. 2006;12(20 Suppl):6250s–7s.PubMedCrossRef

27.

Franken NAP, Hovingh S, Ten Cate R, et al. Relative biological effectiveness of high linear energy transfer α-particles for the induction of DNA-double-strand breaks, chromosome aberrations and reproductive cell death in SW-1573 lung tumour cells. Oncol Rep. 2012;27(3):769–74.PubMed

28.

Baidoo KE, Yong K, Brechbiel MW. Molecular pathways: targeted α-particle radiation therapy. Clin Cancer Res. 2013;19(3):530–7.PubMedCentralPubMedCrossRef

29.

Lassmann M, Nosske D. Dosimetry of ²²³Ra-chloride: dose to normal organs and tissues. Eur J Nucl Med Mol Imaging. 2013;40(2):207–12.PubMedCrossRef

30.

Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23.PubMedCrossRef

31.

Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–55.PubMedCrossRef

32.

Parker C, Heinrich D, O’Sullivan JM, et al. Overall survival benefit of radium-223 chloride (Alpharadin™) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA) [abstract no. 1LBA]. Eur J Cancer. 2011;47(Suppl 2):3.CrossRef

33.

Vogelzang N, Parker C, Nilsson S, et al. Updated analysis of radium-223 dichloride impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 randomized trial (ALSYMPCA) [abstract no. 11 plus poster]. J Clin Oncol. 2013;31(6 Suppl):11.

34.

Parker C, O’Bryan-Tear CG, Bolstad B, et al. Alkaline phosphatase (ALP) normalization and overall survival in patients with bone metastases from castration-resistant prostate cancer (CRPC) treated with radium-223 [abstract no. 49]. J Clin Oncol. 2011;29(7 Suppl):49.

35.

Nilsson S, Sartor AO, Bruland OS, et al. Pain analyses from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases [abstract no. 5038]. J Clin Oncol. 2013;31(15 Suppl):5038.

36.

Tomblyn M, Nilsson S, Vogelzang N, et al. Pain and quality of life (QoL) analyses from the phase 3 randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases [abstract no. 714]. J Urol. 2013;189(4 Suppl):e293.CrossRef

37.

Esper P, Mo F, Chodak G, et al. Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-Prostate instrument. Urology. 1997;50(6):920–8.PubMedCrossRef

38.

Parker CC, Pascoe S, Chodacki A, et al. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol. 2013;63(2):189–97.PubMed

39.

Edge SB, Byrd DR, Compton CC, et al., editors. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.

40.

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guideline^®): prostate cancer (Version 1.2014). 2014. http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed 24 Feb 2014.

41.

Harrison MR, Wong TZ, Armstrong AJ, et al. Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res. 2013;5(1):1–14.PubMedCentralPubMedCrossRef

42.

Bayer. A re-treatment safety study of radium-223 dichloride in subjects with castration-resistant prostate cancer with bone metastases who received an initial course of six doses of radium-223 dichloride 50 kBq/kg every four weeks [ClinicalTrials.gov identifier: NCT01934790]. US National Institutes of Health, ClinicalTrials.gov (online). 2014. http://clinicaltrials.gov/ct2/show/NCT01934790?term=NCT01934790&rank=1. Accessed 24 Feb 2014.

43.

Bayer. A randomized open-label phase IIa study evaluating the efficacy and safety of radium-223 dichloride in combination with abiraterone acetate or enzalutamide in subjects with CRPC who have bone metastases [ClinicalTrials.gov identifier: NCT02034552]. US National Institutes of Health. ClinicalTrials.gov (online). 2014. http://clinicaltrials.gov/ct2/show/record/NCT02034552?term=NCT02034552&rank=1. Accessed 24 Feb 2014.

44.

Algeta ASA. A phase I/IIa study of safety and efficacy of Alpharadin^® with docetaxel in patients with bone metastasis from castration-resistant prostate cancer [ClinicalTrials.gov identifier: NCT01106352]. US National Institutes of Health. ClinicalTrials.gov (online). 2014. http://clinicaltrials.gov/ct2/show/record/NCT01106352?term=NCT01106352&rank=1. Accessed 24 Feb 2014.

Title: Radium-223 Dichloride: A Review of Its Use in Patients with Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases
Authors: Matt Shirley
Paul L. McCormack
Publication date: 01-04-2014
Publisher: Springer International Publishing
Published in: Drugs / Issue 5/2014
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-014-0198-4

ACC 2024 Congress

Springer Medicine

Radium-223 Dichloride: A Review of Its Use in Patients with Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases

Abstract

ACC 2024 Congress

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2014

Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus

Dusty Punch Cards and an Eternal Enigma: High-Density Lipoproteins and Atherosclerosis

Omalizumab: Stepping Outside Our Comfort Zone to Broaden the Number of Those Who Can Benefit

Omalizumab for Severe Asthma: Efficacy Beyond the Atopic Patient?

Pomalidomide: A Review of Its Use in Patients with Recurrent Multiple Myeloma

Delta-9-Tetrahydrocannabinol/Cannabidiol (Sativex®): A Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis